memantine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 111 Diseases   73 Trials   73 Trials   1509 News 


«12345678910111213...3637»
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Review, Journal:  Carbamate as a potential anti-Alzheimer's pharmacophore: A review. (Pubmed Central) -  Sep 11, 2023   
    In this review, we summarize the last 10 years of research conducted on the modification of carbamate with different substituents which primarily target ChE inhibition, reduce oxidative stress, and modulate A? aggregation.
  • ||||||||||  memantine / Generic mfg.
    Trial completion date, Trial primary completion date:  Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions (clinicaltrials.gov) -  Sep 8, 2023   
    P3,  N=100, Recruiting, 
    ASSR and SSHR are robust, non-redundant EEG signals suitable for cross-species analyses that reveal potentially meaningful differences across species, diagnoses and drugs. Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
  • ||||||||||  ketamine / Generic mfg., memantine / Generic mfg., dextromethorphan / Generic mfg.
    FDA event, Journal:  Differential responses of disease-related GRIN variants located in pore-forming M2 domain of N-methyl-D-aspartate receptor to FDA-approved inhibitors. (Pubmed Central) -  Aug 31, 2023   
    Three FDA-approved NMDAR drugs-memantine, dextromethorphan, and ketamine-were chosen based on their ability to bind near the M2 re-entrant loop, potentially rectifying dysregulated NMDAR function by supplementing the reduced voltage-dependent Mg block. These results provide insight of structural determinants of FDA-approved NMDAR drugs at their binding sites in the channel pore and may further define conditions necessary for the use of such agents as potential rescue pharmacology.
  • ||||||||||  memantine / Generic mfg., rivastigmine / Generic mfg.
    Comparative efficacy of pharmacological cognitive treatments in Parkinson () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1514;    
    Rivastigmine is likely to offer the highest clinical, cognitive, and neuropsychiatric benefits in PDD and DLB patients compared to the other cognitive treatments. More large head-to-head randomized controlled trials are needed for better evaluation and enhancement of our current treatment protocols.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Clinical, Review, Journal:  Pharmacological treatment in early rehabilitation after ischemic stroke (Pubmed Central) -  Aug 29, 2023   
    This review provided a summary of the evidence on pharmacological supportive care in early rehabilitation of post-acute ischemic stroke patients. This will make it possible to improve current recommendations with the aim of collaborating with health decision-making for this population.
  • ||||||||||  memantine / Generic mfg., piracetam / Generic mfg., citicoline / Generic mfg.
    Journal:  Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. (Pubmed Central) -  Aug 26, 2023   
    After 3 months, positive results of the neuropsychological examination were reported in both groups. (4) Although there are limited data on the benefit of prescribing pro-cognitive agents in the post-COVID period, our clinical experience suggests that it might be useful in the recovery process from the infection's consequences on cognition for patients with brain pathology.
  • ||||||||||  memantine / Generic mfg.
    Memantine for Pediatric Patients Receiving Cranial Irradiation: A Pilot Study (Room 8) -  Aug 22, 2023 - Abstract #ASTRO2023ASTRO_1237;    
    Memantine is a feasible and well-tolerated addition to multi-modality treatment for pediatric brain tumors. Secondary endpoints of this study and results of the ongoing COG study are awaited to define the value of memantine in this population.
  • ||||||||||  memantine / Generic mfg.
    Journal:  pH-influenced self-assembled stealth nanoscaffolds encapsulating memantine for treatment of Alzheimer's disease. (Pubmed Central) -  Aug 22, 2023   
    Also, behavioural studies have shown a significant (p<0.05) improvement in cognition behaviour among nanostructures- administered animal groups in a scopolamine-induced amnesia model. The designed nanocarrier can also accelerate the treatment strategies for AD by incorporating stem cells and self-assembled nanoscaffolds that could provide a 3D extracellular matrix to facilitate neuron regeneration, hence improving cognition behaviour effectively.
  • ||||||||||  Aduhelm (aducanumab) / Eisai, Biogen, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, Cognex (tacrine) / Shionogi
    Review, Journal:  Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks. (Pubmed Central) -  Aug 21, 2023   
    and anti-tau drugs, mitochondria-targeting and multi-targets, commercially available drugs, bottlenecks encountered in drug development, and the possible targets and therapeutic strategies for future drug development. We hope to present new concepts and methods for future drug therapies for AD.
  • ||||||||||  memantine / Generic mfg.
    Preclinical, Journal:  A hyperthermic seizure unleashes a surge of spreading depolarizations in Scn1a-deficient mice. (Pubmed Central) -  Aug 12, 2023   
    This prolonged neurological aftermath could be suppressed by memantine administration...We also identified a stereotypic SD prodrome, detectable over a minute before the onset of the DC potential shift, characterized by increased motor activity and bilateral EEG frequency changes. Our study suggests that cortical SD is a pathological manifestation in SCN1A-deficient epileptic encephalopathy.
  • ||||||||||  Journal:  Dissipation of twelve organic micropollutants in three different soils: Effect of soil characteristics and microbial composition. (Pubmed Central) -  Aug 2, 2023   
    Dissipation of pollutants that are more susceptible to microbial degradation (e.g., atorvastatin, bisphenol S, and valsartan) seems to be slower for soils possessing the lowest microbial biomass C (C) and total phospholipid fatty acids (PLFA), which also found statistically significant. Our results revealing the persistence of several organic pollutants in agricultural soils, which might impact the quality of these soils, the groundwater, and eventually on the related biota, is of high environmental significance.
  • ||||||||||  ketamine / Generic mfg., memantine / Generic mfg.
    Journal:  NEURODEGENERATION AND NMDA. (Pubmed Central) -  Jul 31, 2023   
    These substances also contribute to the work of the NMDA receptor in the future, and also affect synaptic density. Therefore, it is important to know the composition of the receptor, its downstream signaling pathways, and age-related changes in order to effectively prevent neurodegenerative diseases of the brain.
  • ||||||||||  memantine / Generic mfg.
    Journal:  Alzheimer's and Dementia Guidelines and Tables. (Pubmed Central) -  Jul 29, 2023   
    Approved cholinesterase inhibitors, memantine, and monoclonal antibodies are listed...In these instances, the doses listed are for reference only and should not be considered as recommendations or appropriate use. Physicians should consult the product package labeling for any drug mentioned.
  • ||||||||||  memantine / Generic mfg., LMTX (hydromethylthionine) / TauRx, rivastigmine / Generic mfg.
    Preclinical, Journal:  Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice. (Pubmed Central) -  Jul 18, 2023   
    In summary, traditional anti-dementia drugs impair mitochondrial function while HMT has no adverse effects on mitochondrial respiration in tau-transgenic mice. These results support the further development of HMT as an anti-dementia drug.
  • ||||||||||  memantine / Generic mfg.
    Journal:  The Highs and Lows of Memantine-An Autophagy and Mitophagy Inducing Agent That Protects Mitochondria. (Pubmed Central) -  Jul 18, 2023   
    Intriguingly, low but not high concentrations of memantine lead to the induction of mitophagy. Taken together, our findings have shown that memantine is able to protect the mitochondrial network by preserving its volume upon mitochondrial injury with high concentrations of memantine inducing macroautophagy, whereas low concentrations lead to the induction of mitophagy.
  • ||||||||||  memantine / Generic mfg.
    Journal:  Cognitive impairment in opioid use disorders: Is there a case for use of nootropics? (Pubmed Central) -  Jul 17, 2023   
    Cognition enhancing prescription drugs like donepezil and memantine, which are used in dementias, have shown promise in a small number of studies examining their role in the reversal of opioid-induced cognitive deficits. The authors explore the potential role of nootropics in improvement of cognitive decline associated with OUDs.
  • ||||||||||  chloroquine phosphate / Generic mfg., desipramine / Generic mfg., memantine / Generic mfg.
    Preclinical, Journal:  Characterization of LysoTracker Red uptake by in (Pubmed Central) -  Jul 15, 2023   
    The involvement of lysosomal trapping in response to cationic drugs, including neuroprotectants such as desipramine and memantine, was also suggested by an inhibition study of LTR uptake. This value was 59 times lower than the median lethal concentration (= 79.1
  • ||||||||||  memantine / Generic mfg.
    Review, Journal:  Therapeutic dilemmas: cognitive enhancers and risk of falling in older adults-a clinical review. (Pubmed Central) -  Jul 7, 2023   
    Active, not recruiting --> Completed | N=50 --> 34 | Trial primary completion date: Sep 2022 --> Jun 2023 The use of cognitive enhancers should be regularly reviewed and decisions to deprescribe made on a case-by-case basis, considering both the risks and benefits of stopping these medications.
  • ||||||||||  memantine / Generic mfg.
    Journal:  Adjunctive Memantine for Catatonia Due to Anti-NMDA Receptor Encephalitis. (Pubmed Central) -  Jul 7, 2023   
    The use of cognitive enhancers should be regularly reviewed and decisions to deprescribe made on a case-by-case basis, considering both the risks and benefits of stopping these medications. No abstract available
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Continuation rates of newly prescribed donepezil among patients with Alzheimer () -  Jul 6, 2023 - Abstract #AAIC2023AAIC_9219;    
    Conclusion The AD patients showed a rapid discontinuation of donepezil and subsequent AD treatments by 90 days, and approximately 40% had ceased this therapy after 1.5 years. In view of the limited pharmaceutical options available for AD in Japan, this finding emphasizes the need for AD preventive measures in the pre-clinical stage.